Related Experiment Video
Updated: Sep 30, 2025

The Portable Chemical Sterilizer PCS, D-FENS, and D-FEND ALL: Novel Chlorine Dioxide Decontamination Technologies for the Military
Published on: June 29, 2014
The Road to Bring FDCA and PEF to the Market
Ed de Jong1, Hendrikus Roy A Visser1, Ana Sousa Dias1
1Avantium N.V., Zekeringstraat 29, 1014 BV Amsterdam, The Netherlands.
Abstract:
Biobased polymers and materials are desperately needed to replace fossil-based materials in the world's transition to a more sustainable lifestyle. In this article, Avantium describes the path from invention towards commercialization of their YXY® plants-to-plastics Technology, which catalytically converts plant-based sugars into FDCA-the chemical building block for PEF (polyethylene furanoate). PEF is a plant-based, highly recyclable plastic, with superior performance properties compared to today's widely used petroleum-based packaging materials. The myriad of topics that must be addressed in the process of bringing a new monomer and polymer to market are discussed, including process development and application development, regulatory requirements, IP protection, commercial partnerships, by-product valorisation, life cycle assessment (LCA), recyclability and circular economy fit, and end-of-life. Advice is provided for others considering embarking on a similar journey, as well as an outlook on the next, exciting steps towards large-scale production of FDCA and PEF at Avantium's Flagship Plant and beyond.
More Related Videos
10:20Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
Published on: October 26, 2018
09:18Feeding Experimentation Device FED: Construction and Validation of an Open-source Device for Measuring Food Intake in Rodents
Published on: February 21, 2017
Related Concept Videos
Drug Regulation
Preclinical Development: Overview
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...